Novartis was created in 1996 through the merger of Ciba-Geigy and Sandoz and has a rich history spanning over 200 years. It was ranking number one in sales (57.9 billion US$) among the world-wide industry in 2013. In July 2015, Novartis had a market-cap of around $280 billion making it the largest healthcare company by this metric. They have a talented and diverse workforce of more than 119 000 people of 150 nationalities.
Novartis focuses its business on three leading divisions with strong innovation power and global scale: pharmaceuticals, eye care and generics. These three leading divisions are supported by research organization, the Novartis Institutes for BioMedical Research (NIBR), and a centralized services group, Novartis Business Services, to facilitate collaboration across our divisions, and drive efficiency and productivity gains. They are expanding presence in the emerging markets of Asia, Africa and Latin America, where there is fast-growing demand for access to high-quality medicines and healthcare.
- Zometa and many more
|Type||Public company AG|
|Traded as||SIX: NOVN,
|Key people||Joerg Reinhardt (Chairman), Joseph Jimenez (CEO)|
|Products||Pharmaceuticals, generic drugs, over-the-counter drugs, vaccines, diagnostics, contact lenses, animal health|
|Revenue||US $57.9 billion (2013)|
|Net income||US $12.533 billion (2013)|
|Number of employees||135,696 (2013)|
|Subsidiaries||Ciba Vision, Sandoz, Alcon, Chiron Corporation|